Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24938343 | 1.00 | ADRA1A (0.41) | ADRA1ATSHREPHX2ALDH1A1FOLH1 | |
| SCHEMBL18668826 | 0.85 | MEN1 (0.40) | TSHREPHX2ALDH1A1GAATDP1 | |
| SCHEMBL18686249 | 0.84 | ALDH1A1 (0.44) | TSHRALDH1A1RECQLCNR1DAGLA | |
| SCHEMBL18668793 | 0.84 | ADRA1A (0.48) | ADRA1ATSHREPHX2ALDH1A1GAA | |
| SCHEMBL28542473 | 0.81 | CA12 (0.41) | ADRA1ATSHREPHX2ALDH1A1GAA | |
| SCHEMBL26696268 | 0.80 | ALDH1A1 (0.38) | ADRA1ATSHRALDH1A1TDP1KMT2A | |
| SCHEMBL22699878 | 0.80 | ALDH1A1 (0.44) | ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL21168977 | 0.80 | ALDH1A1 (0.44) | ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL18669011 | 0.80 | ALDH1A1 (0.45) | TSHREPHX2ALDH1A1CNR1TDP1 | |
| SCHEMBL18686180 | 0.80 | TSHR (0.36) | TSHRALDH1A1GAARECQLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4119539-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2023-01-18 | — | — | EP | disclosed |
| EP-4119539-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2023-01-18 | — | — | EP | disclosed |
| EP-3353145-B1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPHARMA LTD (KY) | 2022-09-28 | — | — | EP | disclosed |
| CN-113061089-A | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2021-07-02 | — | — | CN | disclosed |
| US-20210130281-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2021-05-06 | — | — | US | disclosed |
| US-20210130281-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2021-05-06 | — | — | US | disclosed |
| CN-108283000-B | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2021-04-13 | — | — | CN | disclosed |
| US-10941107-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | XW LABORATORIES INC. (KY) | 2021-03-09 | — | — | US | disclosed |
| US-10941107-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | XW LABORATORIES INC. (KY) | 2021-03-09 | — | — | US | disclosed |
| US-20200369599-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XW LABORATORIES INC. (KY) | 2020-11-26 | — | — | US | disclosed |
| US-10640451-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | XW LABORATORIES INC. (KY) | 2020-05-05 | — | — | US | disclosed |
| US-20200039917-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2020-02-06 | — | — | US | disclosed |
| US-20200039917-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2020-02-06 | — | — | US | disclosed |
| US-10457627-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | XW LABORATORIES INC. (KY) | 2019-10-29 | — | — | US | disclosed |
| US-10457627-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | XW LABORATORIES INC. (KY) | 2019-10-29 | — | — | US | disclosed |
| US-20190218168-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2019-07-18 | — | — | US | disclosed |
| US-20190218168-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2019-07-18 | — | — | US | disclosed |
| US-20190194120-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2019-06-27 | — | — | US | disclosed |
| US-20190194120-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2019-06-27 | — | — | US | disclosed |
| WO-2017050259-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XW LABORATORIES INC. (KY) | 2017-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10640451-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | GABRB3, GABRB2, GABRB1 | ADRA1A 836/4885TSHR 3228/4885EPHX2 433/4885 |
| US-10941107-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | GABRB2, GABRB3, GABRB1 | ADRA1A 657/4885TSHR 2992/4885EPHX2 364/4885 |
| US-20200369599-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | GABRB2, GABRB3, GABRB1 | ADRA1A 657/4885TSHR 2992/4885EPHX2 364/4885 |
| US-10457627-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | GABRB3, GABRB2, GABRB1 | ADRA1A 836/4885TSHR 3228/4885EPHX2 433/4885 |
| US-20190194120-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | GABRB3, GABRB2, GABRB1 | ADRA1A 836/4885TSHR 3228/4885EPHX2 433/4885 |
| US-20200039917-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | GABRB3, GABRB2, GABRB1 | ADRA1A 836/4885TSHR 3228/4885EPHX2 433/4885 |
| US-20210130281-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | GABRB2, GABRB3, GABRB1 | ADRA1A 657/4885TSHR 2992/4885EPHX2 364/4885 |
| US-20190218168-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | GABRB3, GABRB2, GABRB1 | ADRA1A 836/4885TSHR 3228/4885EPHX2 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.